Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
ANNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $7.85
Previous CloseN/A
Volume252.73K
Average Volume (3M)1.98M
Market Cap
$163.47M
Enterprise Value$517.89M
Total Cash (Recent Filing)-$2.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 19, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding109,709,820
10 Day Avg. Volume2,621,505
30 Day Avg. Volume1,975,141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)169.36
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap3.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$14.20Price Target Upside853.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Annexon Biosciences News
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalANX005's potential FDA approval in Guillain-Barré Syndrome could lead to significant market share due to its advantages over the current treatment.
Market OpportunityThe annual GBS incidence could be 7K US/15K EU, so GBS could technically be a $1B+ opportunity across the US/EU.
Regulatory UpdatesThe company's current trading at cash suggests a highly skewed risk/reward to the upside.
Bears Say
Price Target ReductionRevaluation of opex assumption and US and EU penetration assumptions for the GBS program reduced the price target.
Share Price DeclineShares are down -55% YTD as additional regulatory clarity on ANX005 in GBS and ANX1502's POC data is awaited.
---
Ownership Overview
13.86% Insiders
16.25% Mutual Funds
0.51% Other Institutional Investors
44.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.28 and its highest was $7.85 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $163.47M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is May 19, 2025 which is in 34 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Mar 03, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.06.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.3.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 109,709,820 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -9.47%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
---
Annexon Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.20 (853.02% Upside)
$14.20 (853.02% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $126.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 50.1%
Last 30 Days ▲ 50.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.45%
12-Months-Change
Fundamentals
Return on Equity
-50.84%
Trailing 12-Months
Asset Growth
17.60%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon Biosciences (ANNX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders. The company operates in the biotechnology sector and is dedicated to the development of innovative treatments that target the complement system, a part of the immune system, to address diseases across multiple therapeutic areas, including neurodegenerative and autoimmune disorders.
---
ANNX Stock 12 Month Forecast
Average Price Target
$14.20
▲(853.02% Upside)
Technical Analysis
Sangamo Biosciences
―
Fulcrum Therapeutics
―
Innate Pharma
―
Tango Therapeutics
―
Nanobiotix
―
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-9.23%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -9.23% per trade.
---